Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018
Cecília G Carvalhaes, Dee Shortridge, Hélio S. Sader, Mariana Castanheira
Abstract
Meropenem-vaborbactam is approved to treat hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), in Europe. Meropenem-vaborbactam activity was evaluated against 3,193 Pseudomonas aeruginosa and 4,790 Enterobacterales isolates causing pneumonia, including VAP, in hospitalized patients in the United States. Susceptibility testing was performed by using the broth microdilution method, and all carbapenem-resistant isolates were submitted for whole-genome sequencing.
Topics & Concepts
Pseudomonas aeruginosaMeropenemPneumoniaMedicineBroth microdilutionMicrobiologyVentilator-associated pneumoniaBacterial pneumoniaAntibioticsBiologyInternal medicineBacteriaAntibiotic resistanceMinimum inhibitory concentrationGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyPneumonia and Respiratory Infections